Residency · Residency · Critical Care

Advanced Mechanical Ventilation: APRV, HFOV, and Rescue Strategies

Airway Pressure Release Ventilation (APRV)

Concept and Physiology

Airway pressure release ventilation is fundamentally a form of continuous positive airway pressure with intermittent brief releases that allow ventilation. The underlying philosophy is that of an "open lung" strategy: a sustained high pressure, referred to as P-high, maintains alveolar recruitment throughout most of the respiratory cycle, while brief, carefully timed releases to a lower pressure level, P-low, generate the pressure gradient necessary for carbon dioxide elimination. Unlike conventional ventilation, APRV allows and encourages spontaneous breathing throughout the entire respiratory cycle, which improves ventilation-perfusion matching, reduces the need for sedation, and helps preserve diaphragmatic function. From a lung protection standpoint, APRV theoretically minimizes both atelectrauma, because alveoli are kept continuously recruited rather than cycling between open and closed states, and volutrauma, because the applied pressure is limited rather than the volume.

Settings and Terminology

The settings in APRV use terminology distinct from conventional ventilation and require specific understanding. P-high, the CPAP level, is typically set between 20 and 35 cmH2O based on the plateau pressure from prior conventional ventilation. T-high, the time spent at P-high, is set at 4 to 6 seconds and determines the duration of the recruitment phase. P-low, the release pressure, is typically set at 0 cmH2O to allow the maximum pressure gradient for ventilation during the brief release. T-low, the release time, is the most critical setting in APRV management, typically ranging from 0.4 to 0.8 seconds, and is set to terminate at 75 percent of the peak expiratory flow rate. This precise timing is essential: a T-low that is too short results in inadequate ventilation and CO2 clearance, while a T-low that is too long causes derecruitment and loss of the auto-PEEP that helps maintain end-expiratory alveolar patency. The target is to terminate the release phase when expiratory flow has decreased to 50 to 75 percent of the peak expiratory flow rate, as assessed on the expiratory flow waveform. Because the mean airway pressure during APRV is typically higher than during conventional ventilation, oxygenation is often improved.

Clinical Application

The primary application of APRV is as a rescue or alternative strategy for refractory hypoxemia in ARDS when conventional low-tidal-volume ventilation has proven insufficient. The preservation of spontaneous breathing during APRV reduces sedation requirements, preserves diaphragm function, and may improve hemodynamics by intermittently generating negative intrathoracic pressure. Release volumes, which serve as the equivalent of tidal volume, should be targeted at 4 to 8 mL/kg ideal body weight, and total minute ventilation, comprising both spontaneous breaths and release volumes, requires careful monitoring to ensure adequate CO2 clearance.

Evidence and Controversy

Despite its theoretical appeal and favorable observational data showing improved oxygenation and hemodynamics, APRV lacks support from large randomized controlled trials comparing it to conventional low-tidal-volume ventilation in ARDS. Significant concerns persist regarding the difficulty of ensuring truly lung-protective tidal volumes, as uncontrolled spontaneous breathing efforts may generate large transpulmonary pressure swings that produce patient self-inflicted lung injury (P-SILI), particularly in severe ARDS with strong spontaneous respiratory drive. For these reasons, APRV is not recommended as a first-line ventilation strategy in current Surviving Sepsis Campaign or American Thoracic Society guidelines for ARDS, though it remains a tool in the rescue armamentarium of experienced centers.

<image>APRV waveform illustration showing pressure-time, flow-time, and volume-time tracings. Pressure tracing shows sustained P-high at 25 cmH2O for 4.5 seconds with brief release to P-low of 0 cmH2O for 0.6 seconds. Flow tracing shows spontaneous breathing activity during P-high phase (small oscillations) and a large expiratory flow spike during the release phase, with annotation at 75% of PEFR showing where T-low should terminate. Volume tracing shows small spontaneous tidal volumes during P-high and larger release volumes during T-low. Include a magnified inset of the expiratory flow during release showing the 75% PEFR cutoff point.</image>

High-Frequency Oscillatory Ventilation (HFOV)

Principles

High-frequency oscillatory ventilation delivers tidal volumes smaller than anatomical dead space, typically 1 to 3 mL/kg, at frequencies of 3 to 15 Hz, equivalent to 180 to 900 breaths per minute. Mean airway pressure is maintained continuously at a level sufficient to sustain alveolar recruitment, while the oscillatory pressure swings around this mean provide gas exchange through mechanisms that differ fundamentally from conventional bulk flow ventilation. These mechanisms include bulk convection in central airways, Taylor dispersion at airway bifurcations, pendelluft between lung units with different time constants, cardiogenic mixing from cardiac oscillations transmitted to adjacent lung tissue, and molecular diffusion at the alveolar level. In theory, HFOV represents the ideal lung-protective strategy by delivering minimal tidal stretch while maintaining sustained recruitment.

Settings

HFOV settings are configured around the mean airway pressure, which is typically set 3 to 5 cmH2O above the mean airway pressure on prior conventional ventilation, with a range of 20 to 35 cmH2O. The oscillation frequency, set at 5 to 8 Hz for adults, determines the size of the oscillatory tidal volume: lower frequencies produce larger tidal volumes, which is useful when CO2 clearance is insufficient. The amplitude, also called delta-P or power, determines the oscillation pressure swing and is the primary control for CO2 removal. The inspiratory time ratio is typically set at 33 percent, creating a 1:2 inspiratory-to-expiratory time ratio, FiO2 is titrated to maintain SpO2 of 88 to 95 percent, and a continuous bias flow of 30 to 60 L/min provides fresh gas to the circuit.

Evidence

Two major randomized controlled trials, both published in 2013, fundamentally altered the landscape for HFOV in ARDS. The OSCAR trial demonstrated no difference in 30-day mortality between HFOV and conventional ventilation in moderate-to-severe ARDS. More concerning was the OSCILLATE trial, which was stopped early because HFOV was associated with significantly increased mortality, 47 percent versus 35 percent, and increased vasopressor requirements. Subsequent meta-analyses confirmed no benefit of HFOV and identified potential harm from hemodynamic compromise attributable to the high intrathoracic pressures generated by sustained elevated mean airway pressure, which reduces venous return and decreases cardiac output. As a result, HFOV is not recommended for routine ARDS management and is relegated to a very limited role as a last-resort rescue option.

Complications

The complications of HFOV are largely consequences of the sustained high intrathoracic pressures and the limitations inherent to the oscillatory delivery system. Hemodynamic compromise from reduced venous return is the most clinically significant complication and was the likely mechanism underlying the excess mortality observed in the OSCILLATE trial. Air trapping and pneumothorax represent ongoing risks. Mucous plugging is problematic because secretion clearance is impaired during oscillation, and standard airway interventions such as suctioning and nebulization cannot be performed effectively while the oscillator is running. Hemodynamic and respiratory monitoring are also technically challenging during HFOV.

Rescue Strategies for Refractory Hypoxemia

Definition of Refractory Hypoxemia

Refractory hypoxemia is generally defined as a PaO2/FiO2 ratio below 100 despite an FiO2 of 0.8 or greater and PEEP of 15 cmH2O or higher, or a PaO2 below 60 mmHg on FiO2 of 1.0 with optimized PEEP. When conventional lung-protective ventilation fails to maintain adequate oxygenation despite optimization of PEEP, driving pressure, and other modifiable factors, rescue therapies should be considered in a systematic, escalating manner.

Recruitment Maneuvers

Recruitment maneuvers aim to open collapsed alveoli by transiently applying pressures above those used during tidal ventilation. Sustained inflation techniques, which apply 30 to 40 cmH2O for 30 to 40 seconds, are rarely used in current practice because of the risk of hemodynamic compromise. Staircase or stepwise recruitment involves incremental PEEP increases with a fixed driving pressure, followed by a decremental PEEP trial to identify the optimal PEEP level. However, the ART trial of 2017 demonstrated that routine recruitment maneuvers with high PEEP titration actually increased mortality compared to the standard low-PEEP ARDSNet approach, fundamentally altering clinical practice. Recruitment maneuvers are no longer routinely recommended, though brief trials may be considered in selected situations such as early ARDS, focal atelectasis, or post-suctioning derecruitment, always with careful hemodynamic monitoring.

Inhaled Pulmonary Vasodilators

Inhaled pulmonary vasodilators selectively dilate the pulmonary vasculature in ventilated lung regions, thereby improving ventilation-perfusion matching without causing systemic vasodilation. Inhaled nitric oxide, delivered at 5 to 40 parts per million, consistently improves oxygenation with typical PaO2/FiO2 increases of 15 to 25 percent, but multiple meta-analyses have failed to demonstrate any mortality benefit. Rebound pulmonary hypertension occurs upon abrupt discontinuation, necessitating a gradual weaning approach, and monitoring for methemoglobinemia and nitrogen dioxide toxicity is required. Inhaled epoprostenol, administered at 10 to 50 ng/kg/min via an in-line nebulizer, achieves similar oxygenation improvements at a fraction of the cost and has a shorter half-life of approximately 6 minutes, producing less rebound. Although no randomized controlled trials directly compare iNO and inhaled epoprostenol, retrospective data suggest clinical equivalence. The role of inhaled pulmonary vasodilators is as a temporizing bridge to definitive therapy such as prone positioning or ECMO, not as a disease-modifying treatment.

Prone Positioning (Covered in Detail in Lecture 08)

The PROSEVA trial established prone positioning for at least 16 hours per day in patients with PaO2/FiO2 below 150 as a mortality-reducing intervention, with 28-day mortality of 16 percent versus 33 percent, yielding a number needed to treat of 6. Prone positioning should be considered before other rescue therapies in moderate-to-severe ARDS, and it is now more accurately classified as a standard of care rather than a rescue therapy.

Venovenous ECMO (Covered in Detail in Lecture 15)

The EOLIA trial of 2018 demonstrated a trend toward mortality benefit with early venovenous ECMO for severe ARDS, with 60-day mortality of 35 percent versus 46 percent that did not reach statistical significance partly due to a 28 percent crossover rate from the control arm. Bayesian post-hoc analysis suggested a greater than 95 percent probability of benefit. ECMO should be considered when PaO2/FiO2 remains below 80 on FiO2 of 1.0 and PEEP of 10 or higher for more than 6 hours, or when pH falls below 7.20 with PaCO2 of 60 or higher despite a respiratory rate of 35. Early transfer to an ECMO center is essential: outcomes are significantly worse when patients are referred in extremis.

<image>Stepwise escalation algorithm for refractory hypoxemia in ARDS. Start with "Conventional lung-protective ventilation (Vt 6 mL/kg, Pplat <30, optimized PEEP)." If PaO2/FiO2 <150: initiate prone positioning (16+ hrs/day). If PaO2/FiO2 <100 despite prone: add inhaled pulmonary vasodilator (epoprostenol or iNO). If still refractory: consider neuromuscular blockade (first 48 hrs). If PaO2/FiO2 <80 or pH <7.20: evaluate for VV-ECMO (contact ECMO center). Side pathway showing APRV as alternative strategy at any point. Each step includes specific criteria, expected PaO2/FiO2 improvement, and time frame for reassessment. Red boxes at each level showing contraindications to each intervention.</image>

Neurally Adjusted Ventilatory Assist (NAVA)

Concept

Neurally adjusted ventilatory assist represents a fundamentally different approach to assisted ventilation by coupling ventilator support directly to the patient's neural respiratory drive. An esophageal catheter equipped with an electrode array measures the electrical activity of the diaphragm (Edi signal), which reflects the phrenic nerve output and the patient's intrinsic respiratory demand. The ventilator delivers pressure assistance proportional to the Edi signal, creating a direct neural-to-ventilator coupling that eliminates the trigger and cycle dyssynchrony inherent in conventional pressure and flow-based ventilator triggering systems.

Settings

The primary adjustable parameter is the NAVA level, expressed in cmH2O per microvolt, which serves as the multiplier applied to the Edi signal. Typical NAVA levels range from 0.5 to 2.0 cmH2O per microvolt, and titration proceeds by increasing the NAVA level until tidal volume and Edi reach a plateau, indicating that the neural-ventilatory coupling is matched. PEEP and FiO2 are set conventionally, and backup ventilation settings are activated if the Edi signal is lost, providing a safety net against apnea.

Clinical Application

Multiple studies have demonstrated that NAVA reduces patient-ventilator dyssynchrony compared to pressure support ventilation, particularly trigger delay and premature or delayed cycling. The improved synchrony may translate to greater patient comfort and reduced sedation requirements. NAVA is especially useful in patients with significant auto-PEEP, where the neural trigger bypasses the flow and pressure trigger limitations that cause ineffective efforts in conventional modes. However, despite improved synchrony, no study has yet demonstrated mortality or ventilator-day benefits with NAVA compared to PSV. Practical limitations include the need for specialized catheter placement, limited availability across institutions, and susceptibility to signal artifacts.

Proportional Assist Ventilation (PAV+)

Concept

Proportional assist ventilation plus is an approach in which the ventilator instantaneously measures the patient's respiratory system elastance and resistance and delivers pressure proportional to the patient's own effort. The clinician sets the percentage of total work of breathing to be assumed by the ventilator, typically 30 to 80 percent, and the ventilator amplifies the patient's breathing pattern rather than imposing a predetermined pressure or volume profile. This creates truly patient-driven ventilation in which the timing, depth, and rate of breathing are determined entirely by the patient's respiratory center.

Clinical Application

PAV+ improves patient-ventilator synchrony compared to PSV and may reduce both over-assistance and under-assistance, as the support is inherently matched to the patient's effort. A distinctive advantage is the real-time display of respiratory mechanics, including compliance, resistance, and work of breathing, which provides valuable clinical information for monitoring disease progression and weaning readiness. Limitations include sensitivity to air leaks, potential artifacts in auto-PEEP measurement, and the absence of large outcome trials demonstrating mortality benefit.

Key Clinical Pearls

• APRV maintains high mean airway pressure for oxygenation while allowing spontaneous breathing — T-low is the critical setting (target 75% of PEFR)
• HFOV has been shown to increase mortality in ARDS (OSCILLATE trial) and should NOT be used routinely
• Recruitment maneuvers are not recommended as routine practice — the ART trial demonstrated harm from aggressive staircase recruitment
• Inhaled pulmonary vasodilators improve oxygenation but not mortality — use as a bridge, not a destination
• The rescue escalation ladder: optimize conventional ventilation → prone positioning → inhaled vasodilators → NMB → ECMO
• Contact an ECMO center early for refractory ARDS — delays in referral worsen outcomes
• NAVA and PAV+ reduce dyssynchrony but have not yet demonstrated mortality benefit in RCTs

References

1. Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med. 2013;368(9):795-805.
2. Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. N Engl J Med. 2013;368(9):806-813.
3. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome. JAMA. 2017;318(14):1335-1345.
4. Habashi NM. Other approaches to open-lung ventilation: airway pressure release ventilation. Crit Care Med. 2005;33(3 Suppl):S228-S240.
5. Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975.

Read this lecture as Markdown